The strong EPS beat and increased revenue, combined with positive pipeline catalysts (WVE-007 Phase 2a initiation, WVE-006 data in May), support a bullish near-term outlook. Watch for the May 18 investor webcast for RestorAATion-2 data and Phase 2a enrollment start for INLIGHT.
Price Chart
Executive Summary
Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, and revenue of $38.2M (up 316% YoY from $9.2M). The beat was driven by higher milestone revenue from the GSK collaboration, while pipeline progress for obesity candidate WVE-007 (FDA-accepted Phase 2a) and RNA editing program WVE-006 (upcoming data) reinforced the bullish thesis.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $38.2M vs $9.2M YoY, up 316%
- Net loss per share -$0.13 vs -$0.29 YoY; beat consensus -$0.34 by 61.8%
- Cash and cash equivalents $544.6M, runway into 3Q 2028
- FDA accepted Phase 2a multidose portion of INLIGHT trial for WVE-007 (obesity); initiation on track for 2Q 2026
- RestorAATion-2 data for WVE-006 (AATD) to be presented in May 2026, with regulatory feedback on accelerated approval expected mid-2026
- GSK collaboration milestone payments contributed to revenue growth
Financial Impact
EPS beat of $0.21 vs consensus, revenue surge of $29M YoY
Risk Factors
- Clinical trial failures or delays for WVE-007 or WVE-006
- Regulatory setbacks on accelerated approval pathway for WVE-006
- Cash burn rate may accelerate with Phase 2a expansion
- Competition from GLP-1 drugs in obesity market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-183563 |
| Document: d135689dex992.htm | 0001193125-26-183563 |
| Document: d135689d8k.htm | 0001193125-26-183563 |
| Document: 0001193125-26-183563-index-headers.html | 0001193125-26-183563 |
| Document: 0001193125-26-183563-index.html | 0001193125-26-183563 |
| Document: 0001193125-26-183563.txt | 0001193125-26-183563 |
| 8-K Data (Synthetic) | 0001193125-26-183563 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $5.41 $4.58 | ▼ −15.34% | ▼ −13.35% | $3.80 (−29.85%) |
May 18, 2026 19w ago | Press Release | $6.14 $5.95 | ▼ −3.09% | ▼ −4.08% | $3.80 (−38.19%) |
Apr 28, 2026 22w ago | 8-K | $7.52 $6.34 | ▼ −15.69% | ▼ −21.15% | $3.80 (−49.53%) |
Apr 28, 2026 22w ago | Press Release | $7.52 $6.38 | ▼ −15.16% | ▼ −20.63% | $3.80 (−49.53%) |
Apr 22, 2026 23w ago | Press Release | $7.38 $6.14 | ▼ −16.80% | ▼ −19.97% | $3.80 (−48.58%) |
Apr 15, 2026 24w ago | DEFA14A | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.80 (−48.16%) |
Apr 15, 2026 24w ago | 8-K | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.80 (−48.16%) |
Mar 26, 2026 27w ago | Press Release | $6.20 $7.18 | ▲ +15.81% | ▲ +5.14% | $3.80 (−38.79%) |
Feb 26, 2026 31w ago | 8-K | $15.36 $6.20 | ▼ −59.64% | ▼ −53.23% | $3.80 (−75.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access